🇺🇸 FDA
Patent

US 11236329

Compound and method for treating myotonic dystrophy

granted A61KA61K31/7088A61K47/64

Quick answer

US patent 11236329 (Compound and method for treating myotonic dystrophy) held by Sarepta Therapeutics, Inc. expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/7088, A61K47/64, A61P, A61P21/00